Vertigo, dizziness, and unsteadiness (VDU) are common symptoms traditionally considered to result from different kinds of vestibular and non-vestibular dysfunctions. The epidemiology of each symptom and how they relate to each other and to migraine, agoraphobia, motion sickness susceptibility (MSS), vaso-vagal episodes (VVE), and anxiety-depression was the object of this population-based study in north-eastern France. A self-administered questionnaire was returned by 2987 adults (age span 18–86 years, 1471 women). The 1-year prevalence for vertigo was 48.3%, for unsteadiness 39.1%, and for dizziness 35.6%. The three symptoms were correlated with each other, occurred mostly (69.4%) in various combinations rather than in isolation, less than once per month, and 90% of episodes lasted ≤2 min. The three symptoms were similar in terms of female predominance, temporary profile of the episodes, and their link to falls and nausea. Symptom episodes of >1 h increase the risk of falls. VDU are much more common than the known prevalence of vestibular disorders. The number of drugs taken increase VDU even when controlling for age. Each VDU symptom was correlated with each co-morbidity in Chi-squared tests. The data suggest that the three symptoms are more likely to represent a spectrum resulting from a range of similar – rather than from different, unrelated – mechanisms or disorders. Logistic regressions controlling for each vestibular symptom showed that vertigo correlated with each co-morbidity but dizziness and unsteadiness did not, suggesting that vertigo is certainly not a more specific symptom than the other two. A logistic regression using a composite score of VDU, controlling for each co-morbidity showed a correlation of VDU to migraine and VVE but not to MSS and not to agoraphobia in men, only in women.

Keywords: epidemiology, vertigo, dizziness, migraine, agoraphobia, motion sickness, anxiety, vaso-vagal
This study sets out to examine the prevalence of vertigo, dizziness, and unsteadiness (VDU) in an adult population. To avoid the problem of the uneven use of terms, it uses purely phenomenological definitions for each. It also makes it possible to establish the co-occurrence of the three symptoms and whether they relate differently to markers of severity for balance disorders like falls and to certain co-morbidities of vestibular disorders.

**MATERIALS AND METHODS**

In the Centre de Médecine Préventive of Nancy Vandoeuvre (Lorraine region, north-eastern France) the nursing staff distributed and collected questionnaires from 3035 adults \( \geq 18 \) years who had volunteered to take part in this study. From adolescence through old age, French people are regularly invited to local centers of preventive medicine to have a free health check-up. The data were recorded anonymously and the study followed the rules of the local ethical committee [comité de protection des personnes (CPP)].

The study used a self-administered questionnaire, which included some basic demographic data and a medical part. The questions on VDU were taken from the vestibular part of the Vertigo Symptom Scale (VSS) (Yardley et al., 1992), which describes to the participant the various symptoms in a way that can easily be understood, leaves little room for interpretation, and does not use the technical terms vertigo or dizziness. The developer of the VSS defined two severe unsteadiness). The developer of the VSS defined two composite scores:

- vertigo short for VDU symptoms lasting for up to 1 h (VDUshort),
- vertigo acute for VDU of \( \geq 1 \) h plus severe unsteadiness, falls, and nausea (VDUacute).

For the composite scores a \( 4\) cut-off was chosen so as to have a significant level of symptoms. Further inclusions were the migraine identifier (Lipton et al., 2003), the Motion Sickness Susceptibility (MSS) Questionnaire (MSSQ) (Golding, 1998), and vaso-vagal episodes (VVE) (Bosser et al., 2006). Markers for agoraphobia and anxiety-depression (AD) were taken from the Marks fear questionnaire (Marks and Mathews, 1979), using the French translation (Cottraux et al., 1987). The maximum score was 40 each, with a cut-off of \( >10 \).

**STATISTICAL METHODOLOGY**

To correct for differences between the sample and the general population of Lorraine, weights were defined for gender, age, and level of education. In each category the weights were the ratio of the proportion in the general population to the observed proportion in the sample. All statistical analyses and tests were performed with weighted data. The statistical package used was SPSS 16.0 for windows.

Bivariate associations were tested by applying Chi-squared tests. Multivariate logistic regression was used, with forward stepping, to explain binary variables from several quantitative and qualitative covariates. Odds-ratios (OR) estimates were derived from these logistic models.

**RESULTS**

Of the 3035 questionnaires returned 2987 (1471 women) were included, after rejecting those with too many missing or unusable data. The average age \( (\gamma) \) was 45.6 for men and 46.2 for women with a similar distribution.

**GLOBAL PREVALENCE OF VESTIBULAR SYMPTOMS**

At least one VDU symptom had occurred at least once in the last 12 months in 59.2% of participants, vertigo (48.3%) was followed by unsteadiness (39.1%) and dizziness (35.6%). About 90% of each symptom episodes were of short (\( \leq 2 \) min) duration and occurred less than once per month (Table 1). The histogram according to frequency and duration for the three symptoms are similar (Figure 1 displays the example of vertigo).

Most participants (69.4%) with symptoms experienced more than one type in various combinations (Table 2). The three symptoms were significantly correlated, as were those with short and long durations.

The risk for falls and severe unsteadiness was significantly increased if symptoms came in combinations rather than in isolation, particularly if the combination included unsteadiness. The risk of nausea was similarly increased for each VDU symptom – and still further in case of symptom combinations.

| Frequency | <2 min | 2–20 min | 20 min–1 h | Hours >12 h |
|-----------|--------|----------|------------|------------|
| 1–3/year  | Vertigo | 25.98*   | 3.26*      | 1.52       | 1.58       | 1.17       |
|           | Dizziness | 19.44   | 2.59       | 1.25       | 1.29       | 0.97       |
|           | Unsteadiness | 22.71  | 2.20       | 1.35       | 1.19       | 1.03       |
| 4–12/year | Vertigo | 14.21*   | 0.92       | 0.66       | 0.61       | 0.14       |
|           | Dizziness | 10.18   | 1.32       | 0.44       | 0.23       | 0.22       |
|           | Unsteadiness | 9.89   | 1.19       | 0.53       | 0.4        | 0.21       |
| >1/month  | Vertigo | 4.42*    | 0.67       | 0.31       | 0.12       | 0.09       |
|           | Dizziness | 2.41    | 0.77       | 0.25       | 0.14       | 0.08       |
|           | Unsteadiness | 2.94  | 0.61       | 0.29       | 0.20       | 0.15       |
| >1/week   | Vertigo | 1.71     | 0.18       | 0.10       | 0.14       | 0.06       |
|           | Dizziness | 1.03    | 0.24       | 0.13       | 0.11       | 0.00       |
|           | Unsteadiness | 1.28   | 0.25       | 0.10       | 0.04       | 0.05       |

Some participants had short as well as long lasting symptoms, therefore the sums for each symptom are higher than the global prevalence indicated in the text. (*Vertigo more prevalent p < 0.01).
Balance-related falls and severe unsteadiness were about three times more frequent if the symptoms lasted >1 h rather than ≤1 h, and this was true for all three symptoms.

**GENDER AND AGE EFFECT**

In women the symptoms were more frequent than in men in most age groups except for ≥70 years. The prevalence was similar across the various age groups except that in women VDUacute was lower for age group 40–49 years (Table 3).

**MEDICATION AND VDU**

Leaving aside contraception, 55.4% took no medication and 4.4% more than six drugs. The number of drugs increased with age. The prevalence of VDUshort and VDUacute increased significantly with the number of drugs, independently of age and gender (Table 4). The risk for VDUshort and VDUacute decreased with age when controlling for drug intake. Balance-related falls increased strongly with five or more drugs but were also mildly increased with exactly one drug. Each VDU symptom was significantly correlated to drug intake in Chi-squared tests, but in a logistic regression controlling age and gender and for each VDU symptom, unsteadiness was the best explanatory factor.

**VDU AND CO-MORBIDITIES**

The global prevalence of migraine was 17.90% with the typical female predominance and decrease over age 50 years, which is similar to European figures (Stovner and Andree, 2010).

The average agoraphobia score was 4.1 which is comparable with data from the literature (Mizes and Crawford, 1986). Prevalence of moderate or severe MSS in men was 3.9% and in women 11.2%, in a study using the same tool (Bosser et al., 2006) in a population of students <30 years, the prevalence were 6.0% for men and 15.7% for women, which is also comparable considering that MSS tends to decrease with age.

Each VDU symptom was highly correlated with every co-morbidity in Chi-squared tests ($p < 0.001$). Table 5 sets out the results of the logistic regression analysis testing the correlation of the co-morbidities with each VDU symptom, controlling for age, gender, and the other VDU symptoms. In this model migraine is correlated with each VDU symptom, VVE and AD with vertigo and dizziness, MSS and agoraphobia only with vertigo.

Anxiety-depression and female gender significantly increased the risk for VDUshort, VDUacute, and all co-morbidities except AD for VVE. A separate multivariate regression analysis was therefore conducted in men and women with and without AD (Table 6).

Migraine increased the risk for VDUshort in men and women and for VDUacute in women, independently of AD.

Vaso-vagal episodes increased the risk for VDUshort in men with and without AD, in women without AD, and for VDUacute in AD men.

In the global analysis the highest OR for MSS were found for female gender 2.53 (CI 1.92–3.34), followed by AD (OR 2.04; CI 1.51–2.76) and migraine (OR 1.48; CI 1.10–1.98). When controlling for AD and gender, migraine was not significant in men but still in non-AD women, MSS did not increase the risk for VDUshort or VDUacute.

In the global analysis the highest risks for agoraphobia were AD (OR 3.48; CI 2.63–4.61) and female gender OR 2.36 (CI 1.78–3.11). When the data were controlled for gender and AD, agoraphobia

---

**Table 2 | The prevalence of combinations of VDU and balance-related fallers, severe unsteadiness, and nausea.**

|                | N = 1514 | N = 1468 | N = 2982 | Fallers (%/Group) | Severe unsteadiness (%/Group) | Nausea (%/Group) |
|----------------|----------|----------|----------|-------------------|-------------------------------|------------------|
| No symt        | 49.6     | 31.7     | 40.8     | 1.2               | 1.1                           | 20.5             |
| Vert only      | 9        | 11.8     | 10.4     | 2.0               | 2.9*                          | 45.3*            |
| Dizz only      | 3.5      | 2.6      | 3.1      | 0.9               | 1.1                           | 46.0*            |
| Vert + dizz    | 5.6      | 7.6      | 6.6      | 3.7               | 4.7*                          | 51.3*            |
| Unstead only   | 4.6      | 4.7      | 4.6      | 4.4               | 5.7*                          | 48.0*            |
| Unstead + vert | 8        | 9.3      | 8.6      | 11.4*             | 11.9*                         | 52.1*            |
| Unstead + dizz | 3.6      | 2.8      | 3.2      | 14.1*             | 17.3*                         | 65.5*            |
| Vert + dizz + unstead | 16.1 | 29.6 | 22.7 | 16.4* | 22.3* | 68.1* |

Vert, vertigo; dizz, dizziness; unstead, unsteadiness. (*p < 0.01).
Table 3 | Percentages per age group and gender comparison for VDUshort, VDUacute, falls, and severe unsteadiness.

| Age groups (years) | VDUshort M/F (%) | p | VDUacute M/F (%) | p | Fallers M/F (%) | p | Severe unsteadiness M/F (%) | p |
|--------------------|-------------------|---|------------------|---|----------------|---|---------------------------|---|
| 19–29              | 21/31 <0.01        |   | 4/12 <0.01       |   | 5/11 <0.05     |   | 5/13 <0.02                |   |
| 30–39              | 12/33 <0.01        |   | 4/12 <0.01       |   | 6/8 ns         |   | 6/10 <0.01                |   |
| 40–49              | 15/29 <0.01        |   | 3/5 ns           |   | 4/7 ns         |   | 3/11 <0.01                |   |
| 50–59              | 14/34 <0.01        |   | 2/12 <0.01       |   | 6/8 ns         |   | 6/12 <0.01                |   |
| 60–69              | 14/21 <0.01        |   | 4/8 ns           |   | 4/8 <0.01      |   | 6/9 ns                    |   |
| ≥70                | 17/17 ns           |   | 7/12 ns          |   | 3/8 ns         |   | 5/7 ns                    |   |

Table 4 | Number of drugs, age, and VDU.

| N       | 436 | 538 | 587 | 558 | 632 | 220 | 2971 |
|---------|-----|-----|-----|-----|-----|-----|------|
| Age groups |
| 18–29 years (%) | 74.3 | 72.1 | 46.8 | 25.8 | 11.8 | 55.4 |
| 30–39 years (%) | 16.4 | 14.8 | 22.0 | 16.9 | 11.8 | 14.7 |
| 40–49 years (%) | 4.3  | 5.3  | 18.1 | 13.1 | 26.4 | 10.3 |
| 50–59 years (%) | 3.3  | 1.9  | 8.1  | 16.5 | 15.0 | 7.3 |
| 60–69 years (%) | 0.1  | 1.1  | 1.9  | 5.7  | 11.1 | 8.2 |
| ≥70 years (%)   | 0.2  | 0.2  | 2.0  | 3.0  | 7.1  | 9.1 |
| VDUshort (OR)   | 1    | 0.77 | 0.68 | 0.65 | 0.33 | 0.27 |
| VDUacute (OR)   | 1    | 0.84 | 0.35 | 0.45 | 0.26 | 0.38 |

The two columns on the right display the % and OR for VDUshort, VDUacute, and balance-related falls adjusted for age, gender, and number of drugs, taking zero drug as reference = 1. The two lower rows the OR for age groups adjusted for number of drugs, gender and age, taking group 18–29 as reference = 1; ns = not significant.

Table 5 | Logistic regression for each co-morbidity controlling for gender, age, and each VDU symptom.

| VDU symptoms   | Vertigo (OR 95% CI) | Dizziness (OR 95% CI) | Unsteadiness (OR 95% CI) |
|----------------|---------------------|-----------------------|--------------------------|
| Migraine       | 1.11 (1.01–1.22)    | 1.36 (1.21–1.52)      | 1.14 (1.03–1.26)         |
| MSS            | 1.18 (1.09–1.26)    | ns                    | ns                       |
| VVE            | 1.31 (1.20–1.43)    | 1.18 (1.08–1.29)      | ns                       |
| Agoraphobia    | 1.32 (1.22–1.41)    | ns                    | ns                       |
| AD             | 1.22 (1.16–1.34)    | 1.23 (1.12–1.36)      | ns                       |

MSS, motion sickness susceptibility; VVE, vaso-vagal episodes; AD, anxiety-depression. (OR 95% CI).

was found to increase the risk for VDUshort, VDUacute in non-AD women. In men the only factor was the combination of AD and MSS.

DISCUSSION

Vertigo, dizziness, and unsteadiness have a high and roughly even prevalence throughout adult life. The three symptoms are correlated with each other, usually appear in short episodes and in various combinations rather than in isolation (Tables 1 and 2), have a similar link to nausea, severe unsteadiness, and balance-related falls, all have a female predominance (Table 3) and all are correlated to each co-morbidity evaluated in this study.

This challenges the traditional view that vertigo is a more specific symptom resulting from dysfunction of the inner ear or its immediate connections in the brain stem and cerebellum (Perrin et al., 2011), whereas dizziness might result from non-acute vestibular disorders but also from a much wider range of causes like metabolic, cardio-vascular, or psychiatric disorders (Baloh, 1996). The present data suggest that the three symptoms are more likely to represent a spectrum resulting from a range of similar – rather than from different, unrelated – mechanisms or disorders. The lack of specificity of vestibular symptoms has also been pointed out in clinical studies in acute vestibular patients (Stanton et al., 2007). This population-based study seems to be in line with this concept, but cannot directly support it as the mechanisms in relatively healthy volunteers and seriously ill patients are likely to be of a different nature.
Occasional and short lasting and isolated symptoms are very common in the population of all ages and might not mean anything serious. On the other hand combinations of symptoms and those lasting for >1 h were correlated with markers of severity like falls.

Previous epidemiological studies found a similar symptom prevalence (Hannaford et al., 2005; Neuhauser et al., 2005) but did not make such a clear distinction between VDU. The study by Neuhauser et al. (2005) found that vertigo/dizziness was about six times – and severe symptoms about three times – more prevalent than a narrower definition of vertigo resulting from vestibular disorders. VDUacute, which reflects symptoms of >1 h duration had a prevalence similar to “vestibular vertigo” as defined in that study.

This points to a big gap between the prevalence of VDU symptoms and that of vestibular diseases. Indeed, the sum of the 1-year prevalence of the most common vestibular disorders – benign paroxysmal positional vertigo 1.6% (von Brevern et al., 2007), vestibular migraine 0.89% (Neuhauser et al., 2006), Menière’s disease 3.5–513/100000 (Alexander and Harris, 2010), and vestibular neuritis annual incidence of 3.5/100000 (Strupp and Brandt, 2009) – is well below 5%. It is not clear how this gap is to be explained, but broadly two, mutually non-exclusive, explanations should be considered. First, the spectrum of vestibular disorders might be wider than captured by the present diagnostic criteria. As the definitions are usually driven by needs of diagnostic certainty, they tend to give more weight to specificity. The consequence is that milder forms of disease presentation may not meet the diagnostic criteria. The second factor could be that VDU also arise from a range non-vestibular conditions, and this explicitly also applies to vertigo. The study gives some suggestions of which factors might play a role.

Drugs might be an important factor (Table 4). There is a clear increase for VDU and falls with the number of drugs taken, and drug consumption goes up with age. It is not obvious how to interpret the finding that consumption of exactly one drug also mildly increased VDU. Each VDU symptom correlated with drug intake but unsteadiness is the symptom best explained by drugs in the logistic regression analysis controlling for vertigo, dizziness, and age. It is well established that drugs increase the risk of

### Table 6 | VDU and co-morbidities controlled for gender and anxiety-depression.

|          | non AD  | VDU short | VDU acute | migraine | MSS | agoraphobia | VVE |
|----------|---------|-----------|-----------|----------|-----|-------------|-----|
| VDU short|         |           |           |          |     |             |     |
| m        |         |           |           |          |     |             |     |
| f        |         |           |           |          |     |             |     |
| VDU acute|         |           |           |          |     |             |     |
| m        |         |           |           |          |     |             |     |
| f        |         |           |           |          |     |             |     |
| migraine |         |           |           |          |     |             |     |
| m        |         |           |           |          |     |             |     |
| f        |         |           |           |          |     |             |     |
| MSS      |         |           |           |          |     |             |     |
| m        |         |           |           |          |     |             |     |
| f        |         |           |           |          |     |             |     |
| agoraphobia |     |           |           |          |     |             |     |
| m        |         |           |           |          |     |             |     |
| f        |         |           |           |          |     |             |     |
| VVE      |         |           |           |          |     |             |     |
| m        |         |           |           |          |     |             |     |
| f        |         |           |           |          |     |             |     |

The upper part of each cell shows data for non-AD, the lower for AD participants. Data for men under diagonal line and for women above. AD, anxiety-depression; VVE, vaso-vagal episodes; MSS, motion sickness susceptibility; VDUshort, composite score of VDU symptoms ≤ 1 h; VDUacute, composite score of VDU symptoms > 1 h.
falls in the elderly (Woolcott et al., 2009), and vertigo/dizziness is a common side-effect of many drugs like anti-hypertensives and sedatives.

A surprising finding is that when controlling for drug intake, VDU decreased with age.

This suggests that drugs or the diseases for which they are prescribed explain a part of VDU, particularly in the elderly and those elderly people who do not need to take any or only a few drugs are very healthy and fall less. On the other hand, in young adults who take little or no medication, the VDU prevalence is similar to older adults, who usually take many drugs. In young adults, factors like migraine and VVE seem to be more important for explaining VDU.

All co-morbidities examined in this study were correlated with each VDU symptom, which suggests they arise from common factors, but each symptom might also have a specific component. In logistic models controlling for each vestibular symptom, age and gender some differences appeared (Table 5). Vertigo was correlated with each co-morbidity, whereas dizziness and unsteadiness were not. This would mean that vertigo is even less, but definitely not more, specific than dizziness or unsteadiness. VVE was correlated with vertigo and dizziness but not unsteadiness. There have traditionally been doubts as to whether orthostatic hypotension could induce spinning vertigo and in an epidemiological survey on orthostatic hypotension (Radtke et al., 2011) vertigo was explicitly excluded. However, recent data have clearly established that a spinning sensation can be observed in primary cardio-vascular conditions (Newman-Toker et al., 2008), and our data suggest that VVE could explain part of the prevalence of dizziness as well as vertigo, particularly among young people and women, where VVE were more prominent.

In this model agoraphobia was only correlated with vertigo and AD with vertigo and dizziness. One might have expected from the data from behavioral and emotional complications of vestibular disorders that dizziness would come out more prominently here rather than vertigo (Ruckenstein and Staab, 2009; Staab, 2012). Migraine was the only co-morbidity correlated to all three VDU symptoms which suggests that from migraine the whole range of vestibular symptoms could arise as opposed to the more narrow definition of vestibular migraine proposed recently (Lempert et al., 2012).

The co-morbidities examined in this study are known to be intercorrelated. Migraine has a link to MSS (Marcus et al., 2005), VVE to MSS (Bosser et al., 2006), agoraphobia to anxiety (Kessler et al., 2006), and all to vertigo. Therefore a logistic model was done to see how they relate when controlling for each other and VDU before and after and separating genders and AD from non-AD because VDU and co-morbidities were higher in women and in AD, except AD in VVE (Table 6).

Migraine has a robust link to VDU short in men and women independently of AD and other co-morbidities, in women also to VDU acute. This finding supports the importance of migraine for VDU.

Vaso-vagal episode has a link to VDU short in non-AD men and women when controlling for the other co-morbidities and suggest it to be an important factor for short lasting vestibular symptoms, particularly in the young and middle aged and is in line with a recent German study (Radtke et al., 2011).

From the global results the main risk factors for MSS were AD and female gender. When controlling for these factors MSS was not linked to VDU and not to migraine in men and only weakly in women. Since migraine and anxiety are more common in women, this could explain why studies in migraine patients showed high rates of MSS (Marcus et al., 2005) but migraine as such might not be the main factor.

In the general analysis the strongest explanatory factors for agoraphobia were AD and female gender. When controlling for gender and AD, VDU increased the risk of agoraphobia in women but not in men. In AD men MSS increased the risk of agoraphobia. The interface of anxiety and vestibular disease is a complex topic (Balaban et al., 2011), from our data the difference between women and men is not explained by migraine and that AD is more important than VDU.

The prevalence of VDU was found to be high across all age groups but tended to decrease in the age group >70. In other studies there was usually an increase with age, particularly in studies focusing on elderly populations of 65–90 year-olds (Jönsson et al., 2004; Stevens et al., 2008; Gassmann and Rupprecht, 2009). In a study encompassing the adult population up to 70 years (Hannerford et al., 2005) there was a mild increase with age in men, but not in women. The findings in the >70 years in our study are probably explained by a recruitment bias. To get to the Centre de Médecine Préventive, persons need to come by their own means. People who are seriously ill or disabled people or who live in institutions would normally not come to this kind of health check because they would be followed up in a different kind of setting. This selection bias is likely to be more important with increasing age. The >70 years group was the smallest in our study, and our weighting correction could probably not control for the selection bias for healthier elderly adults.

ACKNOWLEDGMENTS

The authors are grateful to Thierry Godfroy, MD (Medical Director) for logistical help and to the nurses of the Centre for Preventive Medicine for their contribution to participant recruitment; and to Nathalie Husson, M.Sc., for setting up the database, and to Alexis Lion, Ph.D., for data collection. This study was supported by unrestricted grants from Beaufour Ipsen Pharma, France, and Solvay Pharmaceuticals GmbH, Germany.

REFERENCES

Alexander, T. H., and Harris, J. P. (2010). Current epidemiology of Menière’s syndrome. Otolaryngol. Clin. North Am. 43, 965–970.

Balaban, C. D., Jacob, R. G., and Furman, J. M. (2011). Neurologic bases for comorbidity of balance disorders, anxiety disorders and migraine: neurotherapeutic implications. Expert Rev. Neurother. 11, 379–394.

Baloh, R. W. (1996). “History I. Patient with dizziness,” in Disorders of the Vestibular System, eds R. Baloh and M. Halmagyi (New York: Oxford University Press), 157–170.

Bisdorff, A., Von Brevern, M., Lempert, T., and Newman-Toker, D. (2009). Classification of vestibular symptoms: towards an international classification of vestibular disorders. J. Vestib. Res. 19, 1–13.

Bleakley, B. W., and Goebel, J. (2001). The meaning of the word “vertigo.” Otolaryngol. Head Neck Surg. 125, 147–150.

Stevens et al., 2008; Gassmann and Rupprecht, 2009).
Borel, L., Lopez, C., Péruch, P., and Lacour, M. (2008). Vestibular syndrome: a change in internal spatial representation. Neurophysiol. Clin. 38, 375–389.

Bossu, G., Caillet, G., Guachard, G., Marcon, F., and Perrin, P. H. (2006). Relation between motion sickness susceptibility and vasovagal syncope susceptibility. Brain Res. Bull. 68, 217–226.

Cottraux, J., Bouvard, M., and Messy, P. (1987). Validation and factor analysis of a phobia scale. The French version of the Marks-Mathews fear questionnaire. Encephale 13, 23–29.

Cullen, K. E. (2012). The vestibular system: multimodal integration and encoding of self-motion for motor control. Trends Neurosci. 35, 185–196.

Dai, M., Raphan, T., and Cohen, B. (2007). Labyrinthine lesions and motion sickness susceptibility. Exp. Brain Res. 178, 477–487.

Drachman, D. A., and Hart, C. W. (1972). An approach to the dizzy patient. Neurology 22, 323–334.

Eckhardt-Henn, A., Best, C., Bense, S., Dai, M., Raphan, T., and Cohen, B. (2006). Migrainous vertigo: prevalence and impact on quality of life. Neurology 67, 1028–1033.

Evans, J. V., von Brevern, M., Radtke, A., Lezio, F., Ziese, T., et al. (2006). Migrainous vertigo: prevalence and impact on quality of life. Neurology 67, 1028–1033.

Ferrari, A. M., Shear, K., and Walters, E. A. Jr. (2006). The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 63, 415–424.

Ferrari, A. M., et al. (2006). Migrainous vertigo: prevalence and impact on quality of life. Neurology 67, 1028–1033.

Gassmann, K. G., and Rupprecht, R. (1987). Validation and factor analysis of a phobia scale. The French version of the Marks-Mathews fear questionnaire. Encephale 13, 23–29.

Golding, J. E. (1998). Motion sickness susceptibility questionnaire revised and its relationship to other forms of sickness. Brain Res. Bull. 47, 507–516.

Hannafornd, P. C., Simpson, J. A., Bisset, A. F., Davis, A., McKerrow, W., and Mills, R. (2005). The prevalence of ear, nose and throat problems in the community: results from a national cross-sectional postal survey in Scotland. Fam. Pract. 22, 227–233.

Jonsson, R., Six, E., Landahl, S., and Rosenhall, U. (2004). Prevalence of dizziness and vertigo in an urban elderly population. J. Vestib. Res. 14, 47–52.

Kessler, R. C., Chiu, W. T., Jin, R., Russo, A. M., Shear, K., and Walters, E. E. (2006). The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 63, 415–424.

Kempf, T., Olesen, J., Furman, J., Waterston, J., Seemungal, B., Carey, J., et al. (2012). Vestibular migraine: diagnostic criteria. J. Vestib. Res. 22, 167–172.

Lipton, R. B., Dodick, D., Sadosky, R., Kolodner, K., Endicott, J., Het-tiarachchi, I., et al. (2003). ID Migraine validation study. A self-assessed screener for migraine in primary care: the ID Migraine validation study. Neurology 61, 375–382.

Marcus, D. A., Furman, J. M., and Bab- aban, C. D. (2005). Motion sickness in migraine sufferers. Expert Opin. Pharmacother. 6, 2691–2697.

Marks, I. M., and Mathews, A. M. (1979). Brief self-rating for phobic patients. Behav. Res. Ther. 17, 263–267.

Massion, I., and Woollacott, M. H. (1996). ‘Posture and equilibrium,’ in Balance, Posture and Gait, eds A. M. Bronstein, T. H. Brandt, and M. Woollacott (London: Arnold), 1–18.

Mizes, J. S., and Crawford, J. (1986). Migraine. Behav. Res. Ther. 24, 253–262.

Moulin, T., Sablot, D., Vidry, E., Belahsen, F., Berger, E., Lemoanoud, P., et al. (2003). Impact of emergency room neurologists on patient management and outcome. Eur. Neurol. 50, 207–214.

Nakashima, K., Yokoyama, Y., Shimo-yama, R., Saito, H., Kuno, N., Sano, K., et al. (1996). Prevalence of neurological disorders in a Japanese town. Neuroepidemiology 15, 208–213.

Neuhauser, H. K., Radtke, A., von Brevern, M., Feldmann, M., Lezio, F., Ziese, T., et al. (2006). Migrainous vertigo: prevalence and impact on quality of life. Neurology 67, 1028–1033.

Neuhauser, H. K., von Brevern, M., Radtke, A., Lezio, F., Feldmann, M., Ziese, T., et al. (2005). Epidemiology of vestibular vertigo: a neurologic survey of the general population. Neurology 65, 898–904.

Newman-Toker, D. E., D. F., Stan-ton, V. A., Zee, D. S., Calkino, H., and Robinson, K. A. (2008). How often is dizziness from primary cardiovascular disease true vertigo? A systematic review. J. Gen. Intern. Med. 23, 2087–2094.

Otolaryngol. Clin. North Am. 42, 71–77.

Perrin, F., Vibert, D., and Van Nechel, C. (2011). “Etiology des vertiges,” in EMC Oto-Rhino-Laryngologie (Paris: Elsevier Masson SAS), 1–21. [20-200-A-10].

Radtke, A., Lempert, T., von Brevern, M., Feldmann, M., Lezio, F., and Neuhauser, H. (2011). Prevalence and complications of orthostatic dizziness in the general population. Clin. Auton. Res. 21, 161–168.

Robinson, K. A. (2008). How often is dizziness in primary care. Results from the National Ambulatory Medical Care Survey. J. Fam. Pract. 29, 33–38.

Staab, J. P. (2012). Chronic subjective dizziness. Otolaryngol. Clin. North Am. 42, 71–77.

Sloane, P. D. (1989). Dizziness in pri-
mary care. Results from the National Ambulatory Medical Care Survey. J. Fam. Pract. 29, 33–38.

Staab, J. P., and Runckenstein, M. J. (2003). Which comes first? Psychogenic dizziness versus organic anxiety. Laryngoscope 113, 1714–1718.

Stanton, V. A., Zee, D. S., and Robinson, K. A. (2008). How often is dizziness from primary cardiovascular disease true vertigo? A systematic review. J. Gen. Intern. Med. 23, 2087–2094.

Staab, J. P., and Runckenstein, M. J. (2003). Which comes first? Psychogenic dizziness versus organic anxiety. Laryngoscope 113, 1714–1718.

Stovner, L. J., and Andree, C. (2010). Prevalence of headache in Europe: a review for the EuroQol project. J. Headache Pain 11, 289–299.

Strom, L., and Brandt, T. (2009). Vestibular neuritis. Semin. Neurol. 29, 509–519.

Trend Neurosci. 38, 375–389.

van Brevern, M., Radtke, A., Lezio, F., Feldmann, M., Ziese, T., Lempert, T., et al. (2007). Epidemiolog of benign paroxysmal positional vertigo: a population based study. J. Neurol. Neurosurg. Psychiatry. 78, 710–715.

Woolcott, J. C., Richardson, K. J., Wiens, M. O., Patel, B., Marin, J., Khan, K. M., et al. (2009). Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch. Intern. Med. 169, 1952–1960.

Yardley, L., Masson, E., Verschuurt, C., Haacke, N., and Luxon, L. (1992). Symptoms, anxiety and handicap in dizzy patients: development of the vertigo symptom scale. J. Psychosom. Res. 36, 731–741.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 11 November 2012; paper pending published: 31 December 2012; accepted: 06 March 2013; published online: 22 March 2013.

Citation: Bisdorff A, Bosser G, Gueguen P and Perrin P (2013) The epidemiology of vertigo, dizziness, and unsteadiness and its link to co-morbidities. Front. Neurol. 4:29. doi: 10.3389/fneur.2013.00029

This article was submitted to Frontiers in Neuro-otology, a specialty of Frontiers in Neurology.

Copyright © 2013 Bisdorff, Bosser, Gueguen and Perrin. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.